Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium

Filip Van Hauwermeiren,1,2 Marietta Armaka,3 Niki Karagianni,3,4 Ksanthi Kranidioti,3 Roosmarijn E. Vandenbroucke,1,2 Sonja Loges,5,6 Maarten Van Roy,1,2 Jan Staelens,1,2 Leen Puimège,1,2 Ajay Palagani,7 Wim Vanden Berghe,7 Panayiotis Victoratos,3 Peter Carmeliet,5,6 Claude Libert,1,2 and George Kollias3

1Department of Molecular Biomedical Research, VIB, Ghent, Belgium. 2Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. 3Institute for Immunology, Biomedical Sciences Research Center “Alexander Fleming,” Vari, Greece. 4Biomedcode Hellas SA, Vari, Greece. 5Vesalius Research Center, VIB, Leuven, Belgium. 6Vesalius Research Center, KU Leuven, Leuven, Belgium. 7Department of Biomedical Sciences, Antwerp University, Antwerp, Belgium.

TNF has remarkable antitumor activities; however, therapeutic applications have not been possible because of the systemic and lethal proinflammatory effects induced by TNF. Both the antitumor and inflammatory effects of TNF are mediated by the TNF receptor p55 (p55TNFR) (encoded by the Tnfrsf1a gene). The antitumor effect stems from an induction of cell death in tumor endothelium, but the cell type that initiates the lethal inflammatory cascade has been unclear. Using conditional Tnfrsf1a knockout or reactivation mice, we found that the expression level of p55TNFR in intestinal epithelial cells (IECs) is a crucial determinant in TNF-induced lethal inflammation. Remarkably, tumor endothelium and IECs exhibited differential sensitivities to TNF when p55TNFR levels were reduced. Tumor-bearing Tnfrsf1a+/– or IEC-specific p55TNFR-deficient mice showed resistance to TNF-induced lethality, while the tumor endothelium remained fully responsive to TNF-induced apoptosis and tumors regressed. We demonstrate proof of principle for clinical application of this approach using neutralizing anti-human p55TNFR antibodies in human Tnfrsf1a knockin mice. Our results uncover an important cellular basis of TNF toxicity and reveal that IEC-specific or systemic reduction of p55TNFR mitigates TNF toxicity without loss of antitumor efficacy.

Introduction

In high doses, TNF has remarkable antitumor effects, especially when it is combined with IFN-γ and/or chemotherapeutics (1). Unfortunately, TNF also possesses strong proinflammatory properties, and its use is often accompanied by unacceptable shock symptoms, such as hypotension and organ failure (2–4). Initial studies in patients showed that the maximum tolerated dose (MTD) that can be applied systemically in humans is too low for effective tumor therapy (5). Therefore, therapeutic anticancer application of TNF is limited to local settings, such as isolated limb perfusion, which does not cause systemic toxicity but leads to a very high rate of complete regression of melanomas and soft tissue sarcomas, avoiding amputation of the extremities (6–8). Such successes illustrate that TNF has great potential as an anticancer drug, providing that its toxicity can be reduced (9).

TNF acts by binding to two different receptors, TNF receptor p55 (p55TNFR) (Tnfrsf1a) and p75TNFR (Tnfrsf1b) (10). The p55TNFR was identified as the receptor responsible for both the antitumor effects (11–14) and the shock-inducing proinflammatory signals induced by TNF (12, 15), whereas p75TNFR has been implicated mainly in immune modulation (16–18). The default pathway of p55TNFR signaling, activated in most cell types, leads to cell survival and induction of inflammation, but when cells fail to sufficiently induce these survival signals, an alternate pathway leading to cell death is activated (17, 18). In contrast to initial beliefs, the antitumor effects of TNF are not due to direct induction of cell death of tumor cells. Evidence suggests that TNF directly affects the tumor neovasculature, causing endothelial cell death and vascular dysfunction, leading to tumor necrosis (11, 19, 20).

While the cellular target of the TNF-induced antitumor effects has been elucidated, the mechanisms and the tissues involved in TNF-induced toxicity have only been partially characterized. Recently, a role for necroptosis in TNF-induced toxicity was uncovered (21), but earlier work stresses the importance of TNF-mediated induction of inflammation (e.g., classical antiinflammatory drugs such as steroids and indomethacin protect against TNF toxicity; refs. 22, 23) and of inflammatory mediators, such as IL-17, IL-1, IFN-β, ROS, and iNOS (24–28). Multiple organs, such as intestine, liver, and kidney, suffer from the TNF-induced effects, but it is still unclear which cell type is essential in mediating/initiating the TNF-induced toxicity (2, 29, 30). Of interest, several acute inflammatory conditions in which TNF plays a role have been attributed to effects on the intestinal epithelial cells (IECs) (31, 32).

In this study, we addressed the question of whether TNF’s anticancer and proinflammatory effects can be uncoupled, leading to safer anticancer effects. We report that reducing the expression or availability of p55TNFR strongly dampens the proinflammatory signal without affecting the induction of apoptosis and antitumor effects. Moreover, using conditional Tnfrsf1a reactivation mice, we demonstrate that p55TNFR expression in IECs is sufficient to induce lethal toxicity, while conditional Tnfrsf1a-deficient mice prove that a reduction in p55TNFR expression in IECs significantly protects against lethal TNF-induced toxicity. Our findings uncover an important

Authorship note: Filip Van Hauwermeiren, Marietta Armaka, and Niki Karagianni contributed equally to this manuscript. Claude Libert and George Kollias are co–senior authors.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2013;123(6):2590–2603. doi:10.1172/JCI65624.

cellular basis of systemic TNF toxicity, reveal an IEC-specific haploinsufficiency of p55TNFR, and lay the ground for safe and effective TNF-based antitumor treatment strategies.

**Results**

A 50% reduction of p55TNFR completely protects mice against acute TNF. Three different Tnfrsf1a+/– mouse lines have been generated using different targeting strategies (12–14). All of them were extremely resistant to the lethal inflammatory effect of TNF (Table 1). Hemizygous Tnfrsf1a mice were equally resistant to a single TNF injection and easily tolerated 1,000 μg per mouse (Table 1), i.e., 40-fold more than Tnfrsf1a+/– mice, whose LD50 was 25–30 μg. Upon injection of murine TNF at 100 μg per mouse, Tnfrsf1a+/– mice died from inflammation within 24 hours, but no effects were observed in Tnfrsf1a+/+ mice (data not shown). In addition, TNF-induced IL-6 was absent in the sera of all Tnfrsf1a+/+ lines and was significantly lower (on average 32.5 fold) in Tnfrsf1a+/– mice than in Tnfrsf1a+/+ mice after TNF injection (Figure 1A). The results were independently confirmed in the 3 different types of Tnfrsf1a+/– and Tnfrsf1a+/+ mouse lines. Subsequent experiments were performed on one type of Tnfrsf1a+/+ line, namely the one generated by Rothe et al. (12). In contrast to Tnfrsf1a+/– and Tnfrsf1a+/+ mice, Tnfrsf1a+/+ mice challenged with TNF displayed hypothermia (Figure 1B), sickness symptoms (ruffled fur, diarrhea, and physical inactivity) (Figure 1C), and liver and kidney damage (Figure 1D and Supplemental Figure 2, C and D). Accordingly, the induction of IL-6 after TNF stimulation in Tnfrsf1a+/– mice was significantly lower than that in Tnfrsf1a+/+ mice at 24 hours (Supplemental Figure 2E).

Similar experiments performed in vivo showed that degradation of iKB in the liver was undetectable in TNF-injected Tnfrsf1a+/– mice and was reduced significantly in Tnfrsf1a+/– mice compared with that in Tnfrsf1a+/+ mice (Supplemental Figure 2F). Similar data were obtained in lungs (data not shown). To know whether this leads to reduced TNF-induced toxicity, we injected mice with a single dose of 30 μg TNF and measured the expression of NF-κB−dependent genes in the liver by qPCR 0, 1, and 6 hours after challenge. The expression of IKBa, IL1b, IFNβ, Cxcl9, c-FLIP, and Nox2 was significantly lower (~50%) in Tnfrsf1a+/– mice than that in Tnfrsf1a+/+ mice (Figure 2, D–F, and Supplemental Figure 2, G–I). The same pattern was found for a whole set of other NF-κB−inducible genes, including A20, Icam1, and Vcam1 (data not shown). We also measured serum cytokine levels after TNF stimulus and found that, while no induction was observed in Tnfrsf1a+/– mice, most of them were half-maximally induced in Tnfrsf1a+/+ mice: IL-1β and IL-12p40 (Figure 2, G and H) as well as IL-1α, MIP1β, MCP-1, and CCL5/Rantes (Supplemental Figure 2, J–M). In addition, we found half the amount of NO metabolites in Tnfrsf1a+/– mice compared with that in Tnfrsf1a+/+ mice (Figure 2I).

The strong protection of Tnfrsf1a+/– mice from TNF and the general reduction of expression of genes that have previously been shown to mediate TNF toxicity is consistent with a model in which TNF toxicity is indirect and mediated by several molecules, a combined reduction of which leads to accumulating protection. To verify this hypothesis, we studied the effect of inhibition of multiple proven toxic mediators on injection of 37.5 μg TNF, a 1.5-times LD50 dose. Type I IFNs were inhibited genetically by using Ifnar−/− animals (27), ROS were inhibited using tempol (28), and IL-1 was inhibited using IL-1RA (25). The inhibition of all 3 toxic mediators indeed resulted in a cumulative protection against TNF (Figure 2, J and K).

**Beneficial functions of TNF are preserved in Tnfrsf1a+/– mice.** We investigated whether genetic reduction of p55TNFR expression compromises the beneficial physiological functions of TNF, such as resistance to infection and immune function. First, the Tnfrsf1a+/+, Tnfrsf1a+/–, and Tnfrsf1a+/+ mice were infected with *Listeria monocytogenes*. The Tnfrsf1a+/+ mice succumbed to the infection, but all

**Table 1**

Lethal effect of 3 different doses of i.p. TNF in 3 types of Tnfrsf1a+/– mice

<table>
<thead>
<tr>
<th>TNF doses</th>
<th>100 μg</th>
<th>250 μg</th>
<th>1,000 μg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tnfrsf1a+/–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rothe</td>
<td>0/6</td>
<td>0/6</td>
<td>0/6</td>
</tr>
<tr>
<td>Peschon</td>
<td>0/4</td>
<td>0/2</td>
<td>0/2</td>
</tr>
<tr>
<td>Pfeffer</td>
<td>0/4</td>
<td>0/2</td>
<td>ND</td>
</tr>
<tr>
<td>Tnfrsf1a+/+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rothe</td>
<td>0/8</td>
<td>0/6</td>
<td>0/6</td>
</tr>
<tr>
<td>Peschon</td>
<td>0/8</td>
<td>0/2</td>
<td>0/2</td>
</tr>
<tr>
<td>Pfeffer</td>
<td>0/8</td>
<td>0/2</td>
<td>0/2</td>
</tr>
</tbody>
</table>

The ratio of dead mice to the total number of experimental mice 3 days after injection of the indicated doses of mouse TNF is shown for the Rothe (12), Peschon (13), and Pfeffer (14) homozygous or heterozygous Tnfrsf1a-deficient mouse lines. ND, not done.
Tnfrsf1a+/+ and Tnfrsf1a+/– mice survived (Figure 3A). We then examined the structure of lymphoid organs and humoral immune responses, both dependent on Tnfrsf1a (34), in Tnfrsf1a+/– mice. Spleen sections were made from mice 15 days after immunization with sheep red blood cells (SRBCs). These sections showed that germinal centers and follicular dendritic cell networks were present in Tnfrsf1a+/+ and Tnfrsf1a+/– mice but missing in Tnfrsf1a–/– mice (Figure 3B). In addition, a significant antibody response against SRBCs was detected in Tnfrsf1a+/– mice, while no antibody response was observed in Tnfrsf1a–/– mice (Figure 3C).

**Figure 1**

Resistance of Tnfrsf1a+/– mice to TNF-induced lethal inflammation. (A) Serum IL-6 6 hours after a single i.p. injection of 100 μg TNF in the Rothe (12), Pfeffer (14), and Peschon (13) Tnfrsf1a-deficient mouse lines. ***P < 0.001, compared with Tnfrsf1a+/+. (B) Body temperature (***P < 0.001, compared with Tnfrsf1a+/+ and Tnfrsf1a+/–). (C) Sickness score, (D) serum AST and ALT levels, and (E) intestinal permeability of Tnfrsf1a+/+, Tnfrsf1a+/–, and Tnfrsf1a–/– mice after i.p injection with 50 μg TNF i.p. (or 25 μg i.p. for permeability assay) (n = 8 for all groups). (F) p55TNFR expression, measured by ELISA, in liver samples. (G) Specific binding of 125I-hTNF to BMDMs. In D and F, levels in Tnfrsf1a–/– and Tnfrsf1a+/– were 0, so no statistical significance could be calculated toward Tnfrsf1a+/+ data. Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test).
Figure 2
Signal transduction, gene expression, and cytokine release induced by TNF in Tnfrsf1a+/- mice. (A) Quantification of NF-κB EMSA results in nuclear extracts of BMDMs after stimulation with 10 ng/ml TNF. The graph shows intermediate activation of NF-κB in the Tnfrsf1a+/- samples compared with the Tnfrsf1a+/- and Tnfrsf1a-/- samples. (B and C) Quantification of Western blot results showing JNK and ERK phosphorylation in BMDMs at several time points after stimulation with 10 ng/ml TNF. See also Supplemental Figure 2, B–D, for original blots. (D-F) Intermediate induction of genes coding for IKBA, IL-1β, and IFN-β in livers of mice injected i.p. with 30 μg TNF. Data for Tnfrsf1a-/- mice are not shown, because these mice are not responsive to TNF. (G-I) Intermediate IL-1β, IL-12p40, and NO release in sera of Tnfrsf1a+/- mice injected with 30 μg TNF. (J and K) Cumulative protection against hypothermia and lethality induced by injection of 37.5 μg TNF (1.5-times LD100 in Tnfrsf1a+/- mice), Ifnar1+/- mice (n = 7) were compared with Ifnar1-/- mice (n = 10), which were protected by the ROS inhibitor Tempol (n = 9) or by Tempol and IL-1RA (Anakinra) (n = 10). Numbers in parentheses indicate the number of mice in each group that did not survive. Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test in D–I and log-rank test in K).
and Villin-Cre mice (IEC reactivation) were performed (Supplemental Figure 5A), and the resulting mice were injected with TNF. Only the mice with Villin-Cre–induced reactivation displayed sensitivity for TNF-induced toxicity and lethality, suggesting a crucial role for gut epithelium (Figure 4A). Villin-Cre–reactivated mice, in contrast to nonreactivated Tnfrsf1a+/flNeo mice, showed loss of intestinal permeability upon TNF challenge (ref. 37 and Figure 4B) and increased intestinal Il6 and Il17a mRNA expression (Supplemental Figure 5B). Intestine-derived IL-17 has previously been linked to TNF toxicity (24). Induction of NF-κB–mediated genes by TNF, as shown before in liver (Figure 2), was strongly reduced in intestinal tissues derived from Tnfrsf1a−/− mice compared with that in Tnfrsf1a+/+ mice (Supplemental Figure 3, A–D), whereas TNF-mediated IEC death sensitivity remained unaffected (Figure 4C).

To further investigate the cell-specific requirement of p55TNFR in TNF-induced toxicity, we generated Tnfrsf1a conditional knockout mice (Tnfrsf1afl/fl mice) (the generation and initial characterization of these mice are described in the Methods and in Supplemental Figure 4). Crossing the LysM-Cre, Villin-Cre, or Alfp-Cre strains into the Tnfrsf1afl/fl background resulted in p55TNFR inactivation in myeloid cells, IECs, or hepatocytes, respectively (Supplemental Figure 4, D–F). Only the Villin-Cre Tnfrsf1afl/fl mice significantly resisted TNF-induced toxicity, in contrast to the mice with hepatocyte or myeloid cell Tnfrsf1a deficiency, which remained as sensitive as the controls (Supplemental Figure 5C). Villin-Cre Tnfrsf1afl/fl mice showed reduced intestinal permeability (Supplemental Figure 5D) as well as decreased levels of Il6, Il1b, and Il17a mRNA in intestinal tissue in comparison with that in controls (Supplemental Figure 5E). Interestingly, when TNF was injected in the Villin-Cre Tnfrsf1afl/fl mice, the mice were as resistant to TNF toxicity as the Villin-Cre Tnfrsf1a+/+ mice (Figure 4, D and E). The Villin-Cre Tnfrsf1afl/fl mice exhibited a minimal barrier loss compared with non-TNF-challenged Villin-Cre Tnfrsf1a+/+ control mice, but the barrier was significantly less affected than in TNF-challenged Tnfrsf1a+/+ mice (Figure 4E). We also noticed that IEC death was not defective in Villin-Cre Tnfrsf1a+/+ mice compared with that in p55TNFR-sufficient control mice (Figure 3, C and F), suggesting that TNF-induced systemic death is related to TNF-induced loss of IEC barrier rather than to TNF-induced IEC cell death. In conclusion, these results show that p55TNFR expression levels in the IECs are crucially linked with the induction of intestinal permeability and consequent systemic lethal inflammation.

p55TNFR-dependent apoptosis induction remains functional in Tnfrsf1a−/− mice. To characterize TNF-induced apoptosis in Tnfrsf1a−/− cells, we studied the TNF response of primary fibroblasts derived from Tnfrsf1a−/−, Tnfrsf1a+/−, and Tnfrsf1a+/+ mice. When cells were treated with TNF for 24 hours, intermediate production of IL-6 in supernatant of Tnfrsf1a−/− cells was found (Figure 5A). However, when apoptosis was induced by incubation of cells with TNF and cycloheximide (CHX) for 24 hours, an equal amount of cell death
Figure 4

p55TNFR expression in the intestinal epithelium is a critical determinant for TNF-induced toxicity. (A) Tnfrsf1a\textsuperscript{+/–}, Tnfrsf1a\textsuperscript{+/flNeo}, and Tnfrsf1a\textsuperscript{+/flNeo} mice with tissue-specific Cre expression were injected i.p. with 150 μg TNF, and lethality was monitored. (B) Relative intestinal permeability measured by increase in FITC signal in plasma of Tnfrsf1a\textsuperscript{+/flNeo} (gray) and Tnfrsf1a\textsuperscript{+/flNeo}IEC reactivation mice (black) orally gavaged with 4-kDa FITC-dextran and injected with TNF (0 hour, n = 3; 8 hours, n = 8). (C) IEC death in Tnfrsf1a\textsuperscript{+/–}, Tnfrsf1a\textsuperscript{+/fl}, Tnfrsf1a\textsuperscript{+/flNeo}, and Villin-Cre Tnfrsf1a\textsuperscript{+/flNeo} mice 2 hours after TNF challenge (30 μg, i.p.). Similar amounts of TUNEL-positive cells on ileal sections were detected in all samples (n = 4–5; scale bar: 38 μm). Multiple time points (1, 4, and 8 hours after TNF) were tested, and all showed a similar amount of TUNEL-positive cells in Tnfrsf1a\textsuperscript{+/–} and Tnfrsf1a\textsuperscript{+/fl} IECs. (D) Tnfrsf1a\textsuperscript{fl/fl} (black line), Villin-Cre Tnfrsf1a\textsuperscript{fl/+} (light gray line), and Villin-Cre Tnfrsf1a\textsuperscript{fl/fl} (dark gray line) mice were injected i.v. with 6 μg TNF, and lethality was monitored. (E) Relative intestinal permeability of Villin-Cre Tnfrsf1a\textsuperscript{fl/+} mice compared with Tnfrsf1a\textsuperscript{fl/fl} IECs. (F) IEC death in Tnfrsf1a\textsuperscript{–/–}, Tnfrsf1a\textsuperscript{+/fl}, and Villin-Cre Tnfrsf1a\textsuperscript{+/fl} mice 2 hours after TNF challenge (6 μg, i.v.). Similar amounts of TUNEL-positive cells on ileal sections were detected in all samples (n = 6; scale bar: 38 μm). Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test in B and E, and log-rank test in A and D).
induction was observed in Tnfrsf1a+/– and Tnfrsf1a–/– cells (Figure 5B). Western blot analysis of caspase-8 activation at different time points after TNF/CHX stimulation showed that both Tnfrsf1a+/– and Tnfrsf1a–/– fibroblasts activate similar levels of caspase-8 (Figure 5C). We then induced apoptosis in vivo by injecting TNF plus d-galactosamine (GalN). This combination leads to lethal apoptosis in hepatocytes (38). First, we tested the lethality of two different doses of TNF (0.3 and 0.5 µg) combined with 20 mg GalN. While none of the Tnfrsf1a+/– mice died from the higher dose, all of the Tnfrsf1a–/– mice and 24 out of the 26 Tnfrsf1a+/– mice died within 72 hours (Supplemental Figure 6A). Next, mice were injected with 1 µg TNF and 20 mg GalN and sacrificed when their body temperature dropped to 30 °C, and blood and liver samples were obtained. This occurred at 7 and 7.5 hours in Tnfrsf1a+/– and Tnfrsf1a–/– mice, respectively (Figure 5D). Tnfrsf1a+/– mice were unresponsive to the treatment, and their samples were taken 8 hours after challenge. Liver damage was assessed by measurement of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum (Figure 5E), and apoptosis was measured by DEVDase assay in liver lysates (Figure 5F). AST and ALT levels in Tnfrsf1a+/– and Tnfrsf1a–/– mice were not significantly different, indicating comparable amounts of liver damage. No significant differences were observed in the cleavage of the caspase-3/7 substrate DEVD, indicating comparable induction of apoptosis in Tnfrsf1a+/– and Tnfrsf1a–/– mice. We also studied apoptosis by using the TNF/actinomycin D (TNF/ActD) model and obtained similar results (Supplemental Figure 6, B and C). These results, along with the in vivo results of p55TNFR-mediated death in the intestine (Figure 4, C and F), show that induction of apoptosis by TNF is intact in Tnfrsf1a–/– genotypes.

TNF/IFN-γ–induced apoptosis in tumor endothelium. Effective TNF/IFN-γ–based antitumor therapy induces apoptosis in the neovascularature of tumors, and this is considered key to tumor destruction (7, 20). To study the induction of apoptosis in the tumor endothelium, B16BL6 tumor-bearing Tnfrsf1a+/–, Tnfrsf1a–/–, and Tnfrsf1a+/– mice were injected s.c. parasoleously with 15 µg TNF and 5,000 IU IFN-γ or with PBS, and 24 hours later tumors were excised and apoptosis and caspase-3/7 activation were measured by FACS. The percentage of apoptotic tumor endothelial cells, identified as CD31+CD45–PI– cells, was measured using annexin V and Flica staining, respectively. Figure 5, G and H shows the increase of annexin V–stained cells and Flica-stained cells in TNF/IFN-γ–injected mice compared with that in PBS-treated mice. Tnfrsf1a+/– and Tnfrsf1a–/– mice showed comparable degrees of apoptotic annexin V–positive cells (Figure 5G) and Flica-positive cells containing active caspases (Figure 5H). No increase in annexin V– and Flica-positive cells was observed in Tnfrsf1a+/– mice. TNF/IFN-γ therapy in Tnfrsf1a+/– mice induces tumor regression in the absence of systemic toxicity. We first studied the toxicity profile of standard TNF/IFN-γ therapy, i.e., daily paralesional injection during 10 days, in Tnfrsf1a+/– and Tnfrsf1a–/– tumor-free mice as well as in mice bearing a s.c. B16BL6 melanoma. The tumor regresses well in response to TNF, but it also sensitizes mice to TNF toxicity (39). The LD50 dramatically increased 12.1 fold in tumor-free mice and 8.2 fold in tumor-bearing Tnfrsf1a+/– mice relative to that in Tnfrsf1a–/– mice (Figure 6A and Supplementary Figure 7A). This therapeutic window in Tnfrsf1a–/– mice is close to the required 10-fold factor increase in MTD that was proposed to be essential to increase the safety of TNF to an acceptable level (5). These data suggest that a full and safe antitumor effect may be expected in Tnfrsf1a–/– mice, so we performed antitumor experiments in 2 different models using high doses of TNF/IFN-γ. As shown in Figure 6, B and C, established B16BL6 and Lewis lung carcinoma (LLC) tumors did not regress in Tnfrsf1a+/– mice, and all Tnfrsf1a+/– mice died on the second day of TNF/IFN-γ treatment due to inflammatory shock. In contrast, Tnfrsf1a–/– mice remained healthy, and tumors regressed either completely or to a very large extent after 10 days of treatment. Further proof that p55TNFR expression on host-derived cells but not on tumor cells sensu stricto is linked to the response to TNF/IFN-γ is discussed in Supplemental Figure 7B, where we show that TNF-mediated tumor regression is dependent on p55TNFR expression of the host tissue but not on the tumor cells themselves. To further explore the role of TNF–p55TNFR-mediated toxic signaling through IECs, we performed the antitumor experiment using high doses of TNF/IFN-γ in Villin-Cre Tnfrsf1a+/– mice. Tumor regression occurred equally well in both groups of mice, but survival was significantly better in Villin-Cre Tnfrsf1a+/– mice (Figure 6D). We conclude that a general reduction of p55TNFR levels by 50% or in an IEC–specific manner greatly reduces TNF–induced toxicity without diminishing the antitumor effects. This can make TNF therapy both safe and effective.

Systemic administration of anti-p55TNFR antibody strongly protects against TNF–induced toxicity and leads to safe antitumor therapy. To assess clinical applicability, we used two approaches based on using antibodies to neutralize p55TNFR. First, an anti-mp55TNFR monoclonal antibody protected mice against acute TNF lethality in a dose-responsive way (Figure 7A) and protected B16BL6 tumor-bearing mice against toxicity of TNF/IFN-γ therapy without loss of the antitumor effect, while mice treated with a control antibody showed no significant difference compared with PBS-treated animals (Figure 7, B and C). Elaborate dose-response studies (see Methods) showed an increase of LD50 of 4 times using cotreatment with the antibody compared with the control antibody (Figure 7D and Supplementary Figure 7A). Second, we used a newly developed human TNFRSF1A knockin humanized mouse model (Supplemental Figure 8) and examined the therapeutic efficacy of an anti-human p55TNFR (anti-hp55TNFR) PEGylated Fab’ fragment that neutralizes human but not mp55TNFR. Administration of this antibody (10 mg/kg) prevented acute TNF lethality in human TNFRSF1A knockin mice (Figure 7E) but not in wild-type mice (data not shown). The specific protective effect of coadministration of the antibody in tumor treatment settings was evaluated using the B16BL6 tumor model. Notably, the antibody conferred complete protection against lethality, while the antitumor effect was fully preserved (Figure 7, F and G). The magnitude of the protection studied in an elaborate and standard LD50 experiment was 5 times (Figure 7H). This was a slight improvement over the anti-mp55TNFR antibody, possibly because of better pharmacokinetics of the PEGylated Fab’ fragment compared with the classical anti-mp55TNFR antibody (Supplemental Figure 7A).

Discussion

TNF was first discovered as a cytokine that can cause death of tumor cells and regression of established, solid tumors (4, 40). Shortly afterward, TNF was rediscovered as cachectin, a cytokine responsible for cachexia during chronic infection (41). The dilemma that TNF has strong antitumor effects but is toxic was confirmed in the first clinical trials (42). The effective antitumor dose of TNF was found to be high, close to the MTD, and to be associated with liver toxicity, shock, and bowel necrosis. Lowering the dose of TNF reduced side effects but also the antitumor effect (1).
Figure 5

Induction of apoptosis in Tnfrsf1a−/− mice. (A) IL-6 production in supernatant of Tnfrsf1a+/+, Tnfrsf1a+/−, and Tnfrsf1a−/− fibroblasts (n = 4) 24 hours after TNF stimulation. (B) Measurement of Tnfrsf1a+/+, Tnfrsf1a+/−, and Tnfrsf1a−/− fibroblast survival after stimulation with different concentrations of TNF/CHX (10 μg/ml). Both Tnfrsf1a+/+ and Tnfrsf1a+/− cells undergo apoptosis to a similar extent. (C) Caspase-8 Western blot after TNF/CHX stimulation (1,000 IU/ml and 10 μg/ml) at different time points. The intensity of cleaved caspase-8 (p43/p41) bands was normalized to actin levels. (D) Body temperature of Tnfrsf1a+/+ (n = 4), Tnfrsf1a+/− (n = 5), and Tnfrsf1a−/− (n = 3) mice after i.p. injection with 1 μg TNF plus 20 mg GalN. Tnfrsf1a+/+ and Tnfrsf1a−/− mice were euthanized for sampling when their body temperature dropped to 30°C. (E and F) Hepatocyte cell death parameters after i.p. injection with TNF (1 μg/mouse) plus GalN (20 mg/mouse). After challenge, mice were sacrificed when their body temperature dropped to 30°C. (E) Serum ALT and AST and (F) DEVDase activity in liver. (G and H) Cell death and caspase activation in CD45− CD31+ PI− tumor neovascular endothelial cells. B16BL6 melanoma-bearing mice were injected s.c. paralesionally with 15 μg TNF plus 5,000 IU IFN-γ or with PBS, and 24 hours later tumors were excised and (G) cell death and (H) caspase activation were measured by FACS using annexin V and Flica staining, respectively. Actual percentages of cell death in the PBS-treated animals were 63%, 26%, and 50% (G) and 55%, 55%, and 73% (H) for Tnfrsf1a+/+, Tnfrsf1a+/−, and Tnfrsf1a−/−, respectively. Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test).
Hence, systemic use with high doses of TNF seemed impossible (2, 4, 42) unless a more substantial increase in MTD (up to 10 fold, as proposed; ref. 5) could be obtained.

We demonstrate here that deletion of one functional Tnfrsf1a allele leads to complete protection against challenge with a dose of TNF that is at least 40 times of LD100. This protective haploinsufficiency is likely mediated by dampening the proinflammatory effect of TNF. Hemizygous mice challenged with TNF exhibited significantly reduced inflammation, as shown by a 32-fold reduction in serum IL-6 levels, compared with Tnfrsf1a+/+ mice. This decreased inflammation seems to be due to reduced expression of NF-κB–dependent genes, which was also reflected in downmodulation of a number of cytokines in serum as well as reduction of NO metabolites. These results suggest that the TNF resistance of Tnfrsf1a+/– animals can be explained by a combined reduction of multiple toxic mediators, a hypothesis that we confirmed by inhibiting 3 such toxic mediators (namely IL-1, ROS, and type I IFNs), which led to cumulative protection against TNF. Interestingly, reduction of p55TNFR levels by 50% does not affect physiological functions of TNF, such as antibacterial resistance and secondary lymphoid organ structure and function.

Figure 6
Increased MTD and anticancer effects in Tnfrsf1a−/− mice. Antitumor effect and survival after 10 days of high-dose TNF (50 µg/mouse) plus IFN-γ treatment (5,000 IU). (A) Toxicity of TNF plus IFN-γ in Tnfrsf1a−/− mice (black triangles) and Tnfrsf1a−/− mice (blue circles). Healthy tumor-free mice (continuous line) and B16BL6 melanoma-bearing mice (dotted line) were injected daily with different doses of TNF plus IFN-γ for 10 days. Healthy mice were injected i.p., whereas tumor-bearing mice were injected s.c. pararesealional. The horizontal line represents LD50. (B) B16BL6 melanoma-bearing Tnfrsf1a−/−, Tnfrsf1a−/−, and Tnfrsf1a+/− mice were treated daily by pararesealional s.c. injection with PBS (white symbols; Tnfrsf1a−/−, n = 5; Tnfrsf1a+/−, n = 5; and Tnfrsf1a−/−, n = 4) or high-dose TNF (black symbols; Tnfrsf1a−/−, n = 6; Tnfrsf1a−/−, n = 10; Tnfrsf1a−/−, n = 6) plus IFN-γ. Tnfrsf1a−/− mice had to be euthanized due to large tumor size (indicated by //). (C) LLC-bearing mice were treated daily with PBS (white symbols; Tnfrsf1a−/−, n = 6; Tnfrsf1a−/−, n = 9; Tnfrsf1a−/−, n = 4) or TNF/IFN-γ (black symbols; Tnfrsf1a−/−, n = 5; Tnfrsf1a−/−, n = 13; Tnfrsf1a−/−, n = 9). (D) B16BL6 melanoma-bearing Tnfrsf1afl/fl and Villin-Cre Tnfrsf1afl/fl mice were treated daily by pararesealional injection of 12 µg TNF plus IFN-γ (5,000 IU) for 10 days (Tnfrsf1afl/fl, n = 20 and Villin-Cre Tnfrsf1afl/fl, n = 16). Tnfrsf1afl/fl PBS-treated mice (n = 11) had to be euthanized because of their large tumor size (indicated by //). Data represent mean ± SEM. *P < 0.05, **P < 0.001, Student's t test in B and C (left) and log-rank test (right); in tumor size index (TSI) graphs, compared with PBS- and TNF/IFN-γ–treated Tnfrsf1a−/− (A–C) or TNF/IFN-γ–treated Tnfrsf1a−/− and Villin-Cre Tnfrsf1a−/− (D).
Antibodies against p55TNFR protect against TNF toxicity, increase MTD, and allow safe anticancer therapy. (A) TNF (30 μg) was administered to mice pretreated i.p. with different doses of anti-mp55TNFR monoclonal antibodies (10 mg/ml, n = 5; 5 mg/ml, n = 5; 2.5 mg/ml, n = 4) or PBS (n = 7) or control hamster IgG1 (10 mg/ml, n = 5). (B) Antitumor effects and (C) survival in antitumor experiments on Tnfrsf1a+/+ mice treated for 10 days paralesionally with TNF (25 μg) plus IFN-γ (5,000 IU) (black symbols) or PBS (white symbols) cotreated i.p. daily with PBS (black), control (red), or anti-mp55TNFR antibodies (gray). (D) Toxicity study of TNF/IFN-γ in B16BL6 melanoma-bearing Tnfrsf1a+/+ mice cotreated i.p. with PBS, control antibodies, or anti-mp55TNFR antibody for 10 days. (E) Human TNFRSF1A knockin mice treated i.p. with anti-hp55TNFR monoclonal antibodies (10 mg/ml, n = 6 or 4 mg/ml, n = 6) or control antibody (10 mg/ml, n = 6) and injected with 50 μg TNF or PBS (n = 6). (F) Antitumor effects and (G) survival in antitumor experiments in human TNFRSF1A knockin mice treated with PBS (white symbols) or TNF/IFN-γ (black symbols) and daily i.p. coadministration of PBS (n = 6), control (n = 6), or anti-hp55TNFR antibodies (n = 12). (H) Toxicity study of TNF/IFN-γ in B16BL6 melanoma-bearing human TNFRSF1A knockin mice i.p. cotreated with PBS, control antibody, or anti hp55TNFR antibody. The horizontal line in D and H represents LD50. In the TSI graphs, *** is between PBS and TNF/IFN-γ–treated p55TNFR antibody groups. All data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test in B and F and log-rank test in A, C, E, and G).
The anticancer effect of TNF has been shown to be essentially directed to the neovascular endothelium of tumors, causing endothelial cell death and vascular dysfunction (11, 19, 20). In order to understand and interfere with the mechanism of systemic toxicity of TNF, it is critical to identify cell types that are essential in this process. TNF-induced toxicity previously has been shown to be associated with hypotension (43), liver damage (44), and severe bowel damage (31). In this study, we have made use of 2 informative genetic approaches (i.e., Tnfrsf1a conditional knockout and reactivation mice), which basically provided us with the novel finding that expression of p55TNFR on IECs (and not on endothelial, hepatocyte, or myeloid cells) is essential to cause TNF-induced lethality: mice expressing Tnfrsf1a^+/− levels in IECs in a Tnfrsf1a^−/− background regain TNF sensitivity, while IEC-specific Tnfrsf1a^−/− mice become TNF resistant. We found that TNF-induced inflammatory gene expression in intestinal epithelium is strongly reduced in IEC-specific Tnfrsf1a^−/− mice as well as in Tnfrsf1a^−/− mice and observed a clear association between lethality and loss of intestinal epithelial permeability, which might lead to influx of gut bacteria or bacterial antigens in the system, as previously suggested (31, 32, 45).

p55TNFR-dependent apoptosis was addressed both in vitro by TNF/CHX and in vivo by using the TNF/GalN and TNF/ActD models, in which massive liver apoptosis is induced (38). Fibroblasts derived from Tnfrsf1a^−/− mice were equally sensitive to TNF/CHX–induced apoptosis as cells from Tnfrsf1a^−/− mice and showed no reduced caspase-8 cleavage. In the same Tnfrsf1a^−/− fibroblasts, inflammatory gene induction was strongly reduced compared with that in Tnfrsf1a^+/+ cells, as was found in macrophages. Clearly, the receptor-stimulated activation of transcription factors (as NF-κB) and kinases (MAPK), leading to inflammation, was sensitive to p55TNFR levels, while the activation of caspase-8, leading to apoptosis, was not. Also, in the in vivo models, Tnfrsf1a^+/− and Tnfrsf1a^−/− cells appeared equally responsive and showed comparable levels of caspase activation, although the response in the TNF/GalN and TNF/ActD models appeared slightly delayed in Tnfrsf1a^−/− mice. Also, a similar degree of apoptosis was measured in the typically TNF-sensitive IECs of Tnfrsf1a^+/− and Tnfrsf1a^−/− mice and in the tumor-associated neovascular endothelial cells after treatment with TNF/IFN-γ, since Tnfrsf1a^+/− and Tnfrsf1a^−/− mice showed comparable induction of apoptosis, which is essential for induction of tumor regression (7, 20).

Full antitumor activity was obtained in tumor-bearing mice by daily injections of TNF in combination with IFN-γ for 10 days (1). We investigated the efficacy and potential toxicity of TNF/IFN-γ for 10 days as a treatment for cancer in mice bearing s.c. B16BL6 melanoma. LD50 of a 10-day treatment was increased in Tnfrsf1a^−/− mice by more than 8 fold. This therapeutic window is close to the required 10-fold factor proposed by Lejeune and colleagues (6), who concluded that protecting mice or human patients against a 10-fold toxic dose with retention of anticancer effects should be sufficient to allow systemic therapy with TNF (5). Our results indicate that TNF/IFN-γ treatment is effective against tumors in Tnfrsf1a^−/− mice. We tested this hypothesis in cancer models (B16BL6 and LLC) and found that TNF/IFN-γ therapy indeed led to highly significant tumor regression as well as survival. We conclude that reduction of p55TNFR levels by 50% greatly reduces TNF-induced toxicity without diminishing the antitumor effects. To provide proof of principle for pharmacologic treatment based on our approach, we inhibited p55TNFR both in normal mice (with anti-mp55TNFR antibodies) and in newly generated mutant mice humanized for the TNFRSF1A gene (combined with anti-hp55-TNFR antibodies). Systemic inhibition of p55TNFR was clearly very protective against TNF toxicity, while the antitumor activity remained functional and led to an increase of 4 to 5 times of LD50.

The dosing of p55TNFR-inhibiting antibodies in these experiments is crucial and should lead to a Tnfrsf1a^−/−–like phenotype. Treatment with an insufficient amount of antibody might lead to lethal toxicity, while excessive antibody may block TNF-induced antitumor responses. In order to translate our findings to the clinic, it may be necessary to generate a reliable prediction method to quantify the available or signaling-competent p55TNFR. Future studies should investigate the stability and range of p55TNFR expression in human samples and correlate antibody dosing with TNF-induced responses.

To provide further mechanistic explanation for our findings, we suggest a model in which p55TNFR-induced inflammation is a dynamic system, which, in response to a given TNF stimulus, leads to an adequate activation of NF-κB and MAPK signaling. The magnitude of an inflammatory response not only depends on TNF dosage but also on the amount of available p55TNFR, a mechanism which is also applied in pathophysiology by shedding of the p55TNFR (46). Halving the amount of p55TNFR leads to a halving of the concentration of multiple (n) toxic inflammatory mediators, such as IL-1, IFN-β, IL-17 and others, identified previously (24–28), leading to a robust (2°) combined protection against TNF in Tnfrsf1a^−/− mice. In contrast, TNF-induced cell death of TNF-sensitive cells (IECs, tumor blood vessels) behaves like a binary system, which can still induce the necessary threshold when p55TNFR levels are halved.

In conclusion, we have found a way to increase the safety of the potent anticancer effect of TNF, and we provide evidence that this approach may be directly translatable to the clinic. Our results uncover the cellular basis of systemic TNF toxicity and reveal an IEC-specific haploinsufficiency of p55TNFR, which allows mitigation of TNF toxicity without loss of antitumor efficacy. Our results also highlight the differential quantitative requirements for the p55TNFR in diverse physiological phenomena and provide a framework for the development of more selective therapeutic interventions using the TNF/TNF system.

**Methods**

**Animals.** Tnfrsf1a knockout mice generated by M. Rothe (12) were a gift of H. Bleul (Hoffmann-La Roche, Basel, Switzerland). Other mice deficient in the Tnfrsf1a gene, generated by gene targeting (13, 14), were purchased from The Jackson Laboratories. Most of the experiments were performed on the Tnfrsf1a^−/− mice generated by M. Rothe. There was no specific reason for this choice. Crosses with C57BL/6J mice were performed to obtain Tnfrsf1a^−/− F1 mice. Ifnar1 knockout mice were provided by D. Bonaparte (Gulbenkian Institute of Science, Oeiras, Portugal). nu/nu mice were purchased from Janvier. Mice were maintained in conventional temperature-controlled, air-conditioned animal houses with a 14- to 10-hour light/dark cycle and received food and water ad libitum. Experiments with nu/nu and all other mice were performed in the SPF VIB animal house, and experiments with the Tnfrsf1a^−/− and human TNFRSF1A knockin mice (described in Supplemental Figures 4 and 8, respectively) were performed in the Alexander Fleming Centre animal house. Experiments were performed when the mice were 8–12 weeks old. Conditional Tnfrsf1a reactivation mutant mice (Tnfrsf1a^−/− mice) were previously described (35). In short, the Tnfrsf1a^−/− mice were generated by insertion of a floxed neo into intron 5 of the locus to create this conditional gain-of-function allele. The presence of the neo prevents expression of the gene.
Generation of Tnfrsf1a conditional knockout mice. The Tnfrsf1a−/− mouse strain was generated using standard gene-targeting techniques. In brief, a targeting vector has been generated to induce homologous recombination in ES cells, with exons 2–5 flanked by loxP sites, which upon recombination will result in a frame shift mutation. Upstream of the first loxP site, a flipped neo cassette was inserted to allow for antibiotic resistance selection, and flanking sequences of 3.6 and 2.8 kb 5′ and 3′ completed the vector, fulfilling the homologous recombination requirements. All sequences of the mouse Tnfrsf1a gene were derived by PCR amplification from the respective BAC clone. All exons have been sequenced, and integrity of the sequence was confirmed (Supplemental Figure 4A). The vector was introduced in 129/ola ES cells, and clones having successfully recombined were used for the generation of chimaeras (Supplemental Figure 4B). Chimeric mice were crossed to C57BL/6J for at least 6 generations. After crossing the Tnfrsf1a fl/fl γ × (Supplemental Figure 8 and data not shown). Eight-week-old mice were injected with 6 γ μg streptavidin SAV-PE (clone 55R-286, BD Pharmingen) and 0.75 μg primary hamster anti-mp55TNFR antibody (clone 5SR-286, BD Pharmingen) and 0.75 μg biotinylated goat anti-hamster IgG (Vector Laboratories), followed by 0.5 μg streptavidin SAV-PE (BD Pharmingen), each of which was incubated for 30 minutes at 4°C. p55TNFR expression was measured by flow cytometry on a Coulter EPICS XL-MCL Flow Cytometer (Coulter Co.) and analyzed with the WinMDI 2.8 software.

TNF-binding assay. BMDMs (2 × 10⁶ cells per tube) were incubated for at least 3 hours at 4°C with radiolabeled 125I-hTNF (Amersham), which binds only to p55TNFR. As a control for nonspecific binding, the same experiment was performed in the presence of a 500-fold excess of unlabeled hTNF. After incubation, the cells were washed 4 times with PBS at 4°C to remove the unbound ligand, and radioactivity of the cell pellet was measured with a gamma counter (Beckman). Nonspecific binding was subtracted from the total activity.

p55TNFR ELISA. Whole organ samples were homogenized in ice-cold buffer (PBS, 0.5% CHAPS, protease inhibitors [Complete, Roche]), Homogenates were centrifuged for 30 minutes at 20,000 g and 4°C, after which the supernatant was collected and stored at −80°C. Protein concentration was determined by the Bradford method (Bio-Rad). p55TNFR levels were determined with the Quantikine sp55TNFR ELISA Kit (R&D Systems). The levels shown are normalized to the Tnfrsf1a−/− levels, which were set as 100%.

Statistics. Survival curves (Kaplan-Meier plots) were compared using a log-rank test. Results (mean ± SEM) were compared with a 2-tailed Student’s t test. Final mortality data were compared using a Fisher’s exact test. P values of less than 0.05 were considered significant.


